A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy

Exclusion Criteria

• •1. Radical surgical treatment for primary small cell lung cancer;
• •2. Any anti-tumor treatment received within 4 weeks before the first use of the study drug;
• •3. Untreated or symptomatic central nervous system (CNS) metastases;
• •4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
• •5. History of serious systemic diseases;
• •6. History of serious autoimmune diseases;
• •7. Those receiving treatment of adriamycin or other anthracyclines previously, with the total cumulative adriamycin (or adriamycin-equivalent) dose of \>360 mg/m2.